SCHEMBL6050992

SCHEMBL6050992

O=S(=O)(NCc1ccc(F)cc1)C1CC1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.49
CA9 Q16790 2/20 0.49
CA1 P00915 1/20 0.49
GRIA2 P42262 1/20 0.47
POLB P06746 2/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
PKM P14618 1/20 0.44
USP2 O75604 1/20 0.44
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
NSD2 O96028 2/20 0.43
CA12 O43570 1/20 0.43
CA7 P43166 1/20 0.43
CA14 Q9ULX7 1/20 0.43
LMNA P02545 3/20 0.43
CYP19A1 P11511 1/20 0.42
TP53 P04637 1/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15721401 0.82 KMT2A (0.53) CA9GRIA2SMN1; SMN2KMT2AMEN1
SCHEMBL1115782 0.82 CA2 (0.50) CA2CA9CA1GRIA2KMT2A
SCHEMBL3811125 0.81 CA12 (0.59) CA2CA9CA1GRIA2POLB
SCHEMBL18109262 0.79 GRIA2 (0.41) CA2CA9CA1GRIA2SMN1; SMN2
SCHEMBL4978574 0.79 SMN1; SMN2 (0.51) GRIA2POLBRAB9ASMN1; SMN2USP2
SCHEMBL10187817 0.78 GRIA2 (0.44) CA2CA1GRIA2RAB9ASMN1; SMN2
SCHEMBL6050965 0.78 HTT (0.58) CA2CA9CA1SMN1; SMN2USP2
SCHEMBL4426600 0.78 KMT2A (0.61) GRIA2POLBKMT2AMEN1TDP1
SCHEMBL2315910 0.78 GRIA2 (0.42) GRIA2KMT2AMEN1
SCHEMBL1115783 0.77 CA2 (0.55) CA2CA1POLBRAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10344031-B2 Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (Trk) inhibitors DR. REDDY'S LABORATORIES LTD. (IN) 2019-07-09 US disclosed
US-20180354951-A1 Substituted Pyrazolo[1,5-a] Pyridine As Tropomyosin Receptor Kinase (trk) Inhibitors DR. REDDY'S LABORATORIES LTD. (IN) 2018-12-13 US disclosed
US-9670207-B2 Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (Trk) inhibitors DR. REDDY'S LABORATORIES LTD. (IN) 2017-06-06 US disclosed
US-20160264572-A1 SUBSTITUTED PYRAZOLO[1,5-A] PYRIDINE AS TROPOMYOSIN RECEPTOR KINASE (TRK) INHIBITORS DR. REDDY'S LABORATORIES LTD. (IN) 2016-09-15 US disclosed
EP-1505945-A4 SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2006-11-22 EP disclosed
EP-1505945-A2 SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Pharma Company (US) 2005-02-16 EP disclosed
WO-2004043339-A2 SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180354951-A1 Substituted Pyrazolo[1,5-a] Pyridine As Tropomyosin Receptor Kinase (trk) Inhibitors MUSK, DMPK, PNCK CA2 3771/4885CA9 4565/4885CA1 4699/4885
US-20160264572-A1 SUBSTITUTED PYRAZOLO[1,5-A] PYRIDINE AS TROPOMYOSIN RECEPTOR KINASE (TRK) INHIBITORS MUSK, DMPK, PNCK CA2 3771/4885CA9 4565/4885CA1 4699/4885
US-10344031-B2 Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (Trk) inhibitors MUSK, DMPK, PNCK CA2 3771/4885CA9 4565/4885CA1 4699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.